KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Non-Current Deffered Revenue: 2009-2024

Historic Non-Current Deffered Revenue for Novavax (NVAX) over the last 15 years, with Dec 2024 value amounting to $446.8 million.

  • Novavax's Non-Current Deffered Revenue fell 22.95% to $397.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $397.1 million, marking a year-over-year decrease of 22.95%. This contributed to the annual value of $446.8 million for FY2024, which is 28.19% down from last year.
  • Per Novavax's latest filing, its Non-Current Deffered Revenue stood at $446.8 million for FY2024, which was down 28.19% from $622.2 million recorded in FY2023.
  • Novavax's Non-Current Deffered Revenue's 5-year high stood at $622.2 million during FY2023, with a 5-year trough of $172.5 million in FY2021.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $446.8 million (2024), whereas its average is $416.1 million.
  • Per our database at Business Quant, Novavax's Non-Current Deffered Revenue spiked by 246.80% in 2023 and then decreased by 28.19% in 2024.
  • Yearly analysis of 4 years shows Novavax's Non-Current Deffered Revenue stood at $172.5 million in 2021, then climbed by 4.01% to $179.4 million in 2022, then surged by 246.80% to $622.2 million in 2023, then declined by 28.19% to $446.8 million in 2024.